OpenLB
Open Library of Bioscience
Advanced Search
European journal of medical research
Nov 01, 2023;28 (1): 475.

The emerging roles of N6-methyladenosine RNA modifications in thyroid cancer.

Xiaoxin Xu, Jiayao Zhao, Mingyue Yang, Lutuo Han, Xingxing Yuan, Wencheng Chi, Jiakang Jiang
Author Information
  1. Xiaoxin Xu: Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, People's Republic of China.
  2. Jiayao Zhao: Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, People's Republic of China.
  3. Mingyue Yang: The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
  4. Lutuo Han: Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, People's Republic of China.
  5. Xingxing Yuan: Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, People's Republic of China.
  6. Wencheng Chi: Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, People's Republic of China. 15104535400@163.com.
  7. Jiakang Jiang: Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, People's Republic of China. jiangjiakang1964@163.com.
PMID: 37915103 DOI: 10.1186/s40001-023-01382-2

Abstract

Thyroid cancer (TC) is the most predominant malignancy of the endocrine system, with steadily growing occurrence and morbidity worldwide. Although diagnostic and therapeutic methods have been rapidly developed in recent years, the underlying molecular mechanisms in the pathogenesis of TC remain enigmatic. The N6-methyladenosine(m6A) RNA modification is designed to impact RNA metabolism and further gene regulation. This process is intricately regulated by a variety of regulators, such as methylases and demethylases. Aberrant m6A regulators expression is related to the occurrence and development of TC and play an important role in drug resistance. This review comprehensively analyzes the effect of m6A methylation on TC progression and the potential clinical value of m6A regulators as prognostic markers and therapeutic targets in this disease.

Keywords

N6-Methyladenosine Prognosis Progression Thyroid cancer Treatment

References

  1. J Hematol Oncol. 2020 Aug 27;13(1):117 [PMID: 32854717]
  2. Cell Death Dis. 2022 Apr 18;13(4):358 [PMID: 35436987]
  3. Mol Ther. 2021 May 5;29(5):1821-1837 [PMID: 33484966]
  4. Proc Natl Acad Sci U S A. 1974 Oct;71(10):3971-5 [PMID: 4372599]
  5. Nat Chem Biol. 2011 Oct 16;7(12):885-7 [PMID: 22002720]
  6. J Exp Clin Cancer Res. 2022 Jan 28;41(1):42 [PMID: 35090515]
  7. Sci Rep. 2017 Feb 13;7:42271 [PMID: 28205560]
  8. DNA Cell Biol. 2020 Oct 15;: [PMID: 33054406]
  9. J Biol Chem. 2010 May 7;285(19):14701-10 [PMID: 20167602]
  10. Nucleic Acids Res. 2020 Sep 18;48(16):9250-9261 [PMID: 32813009]
  11. Mol Cell. 2016 Jul 21;63(2):306-317 [PMID: 27373337]
  12. Cell Prolif. 2019 May;52(3):e12564 [PMID: 30938030]
  13. Int J Mol Sci. 2022 May 22;23(10): [PMID: 35628623]
  14. PLoS Genet. 2018 May 25;14(5):e1007412 [PMID: 29799838]
  15. Front Immunol. 2022 Nov 01;13:995645 [PMID: 36389678]
  16. Mol Cell Biochem. 2023 Apr;478(4):729-741 [PMID: 36070054]
  17. Front Immunol. 2022 Aug 11;13:914977 [PMID: 36032107]
  18. J Clin Endocrinol Metab. 2022 Jan 18;107(2):474-490 [PMID: 34562008]
  19. Genes Dev. 2015 Oct 1;29(19):2037-53 [PMID: 26404942]
  20. Onco Targets Ther. 2020 Feb 21;13:1605-1612 [PMID: 32158230]
  21. Int J Biol Sci. 2022 Mar 28;18(7):2744-2758 [PMID: 35541906]
  22. Nature. 2021 May;593(7860):597-601 [PMID: 33902106]
  23. Cell Rep. 2017 Aug 29;20(9):2262-2276 [PMID: 28854373]
  24. Pathology. 2017 Apr;49(3):229-237 [PMID: 28279477]
  25. Eur J Med Chem. 2022 Feb 15;230:114118 [PMID: 35063732]
  26. Am J Otolaryngol. 2020 Jul - Aug;41(4):102547 [PMID: 32474328]
  27. Med Oncol. 2022 Sep 29;39(12):235 [PMID: 36175777]
  28. Cell Res. 2018 Jun;28(6):616-624 [PMID: 29789545]
  29. Mol Cancer. 2020 Jun 8;19(1):104 [PMID: 32513173]
  30. Front Endocrinol (Lausanne). 2022 Jun 03;13:857765 [PMID: 35721711]
  31. Nat Rev Genet. 2014 May;15(5):293-306 [PMID: 24662220]
  32. Oxid Med Cell Longev. 2022 Mar 11;2022:9974639 [PMID: 35308166]
  33. Mol Cell. 2017 Oct 19;68(2):374-387.e12 [PMID: 29033321]
  34. Front Oncol. 2021 Feb 23;11:624395 [PMID: 33718187]
  35. Mol Cancer. 2020 May 12;19(1):88 [PMID: 32398132]
  36. Clin Transl Oncol. 2023 Jan;25(1):269-282 [PMID: 36163443]
  37. Aging (Albany NY). 2020 Nov 20;12(23):23931-23944 [PMID: 33237039]
  38. PeerJ. 2022 Nov 10;10:e14334 [PMID: 36389416]
  39. Curr Med Chem. 2022;29(5):924-933 [PMID: 34269659]
  40. Int J Mol Sci. 2022 Sep 29;23(19): [PMID: 36232810]
  41. Cancer Cell. 2019 Apr 15;35(4):677-691.e10 [PMID: 30991027]
  42. Trends Biochem Sci. 2012 Aug;37(8):309-16 [PMID: 22626471]
  43. PLoS One. 2020 Jan 15;15(1):e0227647 [PMID: 31940410]
  44. Cell Res. 2014 Feb;24(2):177-89 [PMID: 24407421]
  45. Best Pract Res Clin Endocrinol Metab. 2023 Jan;37(1):101664 [PMID: 35534363]
  46. Front Pharmacol. 2022 Jun 16;13:933332 [PMID: 35784761]
  47. Nat Commun. 2013;4:1798 [PMID: 23653210]
  48. Mol Cancer. 2021 Apr 13;20(1):67 [PMID: 33849552]
  49. Biomolecules. 2023 Jan 27;13(2): [PMID: 36830614]
  50. Cell. 2015 Sep 10;162(6):1299-308 [PMID: 26321680]
  51. Mol Cancer. 2022 Jul 18;21(1):148 [PMID: 35843942]
  52. Sci Adv. 2018 Oct 03;4(10):eaar8263 [PMID: 30306128]
  53. Nat Chem Biol. 2014 Feb;10(2):93-5 [PMID: 24316715]
  54. J Hematol Oncol. 2020 Apr 10;13(1):35 [PMID: 32276589]
  55. Mol Cancer. 2022 Feb 14;21(1):52 [PMID: 35164788]
  56. Cell Res. 2017 Mar;27(3):315-328 [PMID: 28106072]
  57. Cell Mol Life Sci. 2013 Aug;70(15):2657-75 [PMID: 23069990]
  58. Nucleic Acids Res. 2019 Sep 5;47(15):7719-7733 [PMID: 31328227]
  59. Mol Cancer. 2019 Dec 4;18(1):176 [PMID: 31801551]
  60. Am J Cancer Res. 2022 Jul 15;12(7):3259-3279 [PMID: 35968348]
  61. Cancer Cell Int. 2021 Jul 19;21(1):385 [PMID: 34281544]
  62. Cancer Lett. 2022 Feb 28;527:10-23 [PMID: 34896211]
  63. Mol Cell. 2013 Jan 10;49(1):18-29 [PMID: 23177736]
  64. Nat Cell Biol. 2018 Mar;20(3):285-295 [PMID: 29476152]
  65. Cancer Sci. 2023 Jun;114(6):2318-2334 [PMID: 36851875]
  66. Lancet. 2016 Dec 3;388(10061):2783-2795 [PMID: 27240885]
  67. Drug Discov Today. 2021 Nov;26(11):2559-2574 [PMID: 34126238]
  68. Semin Cancer Biol. 2022 Nov;86(Pt 3):18-31 [PMID: 35643219]
  69. CA Cancer J Clin. 2013 Nov-Dec;63(6):374-94 [PMID: 23797834]
  70. Eur J Med Chem. 2022 Aug 5;238:114500 [PMID: 35675754]
  71. Mol Cell. 2018 Mar 15;69(6):1028-1038.e6 [PMID: 29547716]
  72. Trends Cancer. 2022 Jul;8(7):598-614 [PMID: 35346615]
  73. Cancers (Basel). 2022 Mar 01;14(5): [PMID: 35267576]
  74. Gland Surg. 2023 Jan 1;12(1):39-53 [PMID: 36761480]
  75. Nucleic Acids Res. 2020 Jun 19;48(11):6251-6264 [PMID: 32406913]
  76. J Hematol Oncol. 2022 Jan 21;15(1):8 [PMID: 35063010]
  77. Aging (Albany NY). 2023 Feb 15;15(3):846-865 [PMID: 36791151]
  78. Gene. 2002 Apr 3;287(1-2):49-54 [PMID: 11992722]
  79. Cell. 2017 Jun 15;169(7):1187-1200 [PMID: 28622506]
  80. Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):20159-20170 [PMID: 32747553]
  81. J Hematol Oncol. 2019 Nov 22;12(1):121 [PMID: 31757221]
  82. J Cancer. 2020 Jul 6;11(17):5187-5197 [PMID: 32742465]
  83. Mol Cancer. 2022 Jan 28;21(1):32 [PMID: 35090469]
  84. Nature. 2014 Jan 2;505(7481):117-20 [PMID: 24284625]
  85. Int J Mol Sci. 2022 Mar 30;23(7): [PMID: 35409166]
  86. Nature. 2016 Sep 15;537(7620):369-373 [PMID: 27602518]
  87. Biochem Biophys Rep. 2016 Feb 10;5:476-481 [PMID: 28955855]
  88. Pathol Res Pract. 2021 Sep;225:153550 [PMID: 34340128]

MeSH Term

Humans
Thyroid Neoplasms
RNA

Chemicals

RNA
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0TCm6AcancerRNAregulatorsThyroidoccurrencetherapeuticN6-methyladenosinepredominantmalignancyendocrinesystemsteadilygrowingmorbidityworldwideAlthoughdiagnosticmethodsrapidlydevelopedrecentyearsunderlyingmolecularmechanismspathogenesisremainenigmaticmodificationdesignedimpactmetabolismgeneregulationprocessintricatelyregulatedvarietymethylasesdemethylasesAberrantexpressionrelateddevelopmentplayimportantroledrugresistancereviewcomprehensivelyanalyzeseffectmethylationprogressionpotentialclinicalvalueprognosticmarkerstargetsdiseaseemergingrolesmodificationsthyroidN6-MethyladenosinePrognosisProgressionTreatment

Similar Articles

Cited By